Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
OP

WKN: A3EG3E | ISIN: GG00BMFG5F62 | Ticker: OK11
NASDAQ
18.11.26 | 21:59
1,100 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OKYO PHARMA LIMITED Chart 1 Jahr
5-Tage-Chart
OKYO PHARMA LIMITED 5-Tage-Chart

Aktuelle News zur OKYO PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.11.OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London358LONDON and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
► Artikel lesen
12.11.OKYO Pharma Ltd - 6-K, Report of foreign issuer1
05.11.OKYO Pharma to Present at the Stifel 2026 Healthcare Conference337LONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
► Artikel lesen
06.10.OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain393NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal painFirst patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN LONDON and NEW YORK...
► Artikel lesen
06.10.OKYO Pharma Ltd - 6-K, Report of foreign issuer2
29.09.OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences379OKYO demonstrates continued commitment to optometry and ophthalmology LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical...
► Artikel lesen
29.09.OKYO Pharma Ltd - 6-K, Report of foreign issuer2
OKYO PHARMA Aktie jetzt für 0€ handeln
09.09.OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026430Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal painLONDON and NEW YORK, Sept. 09,...
► Artikel lesen
08.09.OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference435LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
► Artikel lesen
08.09.OKYO Pharma Ltd - 6-K, Report of foreign issuer2
28.07.OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer324LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
► Artikel lesen
27.07.OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026417LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
► Artikel lesen
27.07.OKYO Pharma Ltd - 6-K, Report of foreign issuer1
23.07.OKYO Pharma Announces Purchase of Shares by Director395LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
► Artikel lesen
23.07.OKYO Pharma CEO purchases 15,000 shares at $1.54 each2
23.07.OKYO Pharma Announces Purchase of Shares by Chief Executive Officer380LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
► Artikel lesen
22.07.OKYO Pharma Announces Purchase of Shares by Chairman370LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
► Artikel lesen
22.07.OKYO Pharma executive purchases 3,500 shares at $1.40 each2
22.07.OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director385LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
► Artikel lesen
22.07.OKYO Pharma Announces Purchase of Shares by Chief Medical Officer377LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic...
► Artikel lesen
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1